

## **Programme**

25–27 September 2017  
Prague, Czech Republic

### **Programme committee chairs**

Ladislav Dušek (Czech Republic)  
Director of the Institute of Health Information  
And Statistics of the Czech Republic

Thierry Ponchon (France)  
United European Gastroenterology  
Chair of the Public Affairs Committee

**Monday, 25 September 2017**

**Prevention, screening and early diagnosis of serious diseases in the light of current evidence and practical experiences – symposium in Czech language**

You can visit conference website (in Czech language):  
<http://prevon.uzis.cz/>

**Tuesday, 26 September 2017**

9:30–11:30

**Workshop: Implementing innovations in colorectal cancer screening: transition to quantitative immunochemical testing**

**Chairs:** O. Májek, S. Halloran

9:30–9:50

Faecal testing in colorectal cancer screening: state of art  
S. Halloran

9:50–10:00

Czech National Coordination Centre for Prevention of Serious Diseases: platform for systematic introduction of innovations to early disease detection  
O. Májek

10:00–10:20

Implementation of population-based faecal occult blood testing and transition to immunochemical tests: experience from England  
S. Halloran

10:20–10:35

Role of primary care in population-based colorectal cancer screening: current situation and future prospects  
B. Seifert

10:35–10:50

Quantitative immunochemical tests: evidence on accuracy and implementation considerations in the Czech Republic  
P. Kocna

10:50–11:05

Quality-assured immunochemical testing – proposal for a pilot project in the Czech Republic  
O. Májek, Š. Suchánek

11:05–11:30

Structured discussion & wrap-up

11:30–12:00 Lunch break

12:00–13:00

**Press conference**

13:00–13:30

**Opening ceremony**

## Symposium in English language

### Digestive Cancers

13:30–15:50

#### **Pancreatic cancer: The main challenge**

**Chairs:** P. Poc, J. Rosendahl, A. Stunt

13:30–13:40

General introduction

P. Poc, L. Dušek

13:40–14:00

How to identify high-risk population

N. Malats

14:00–14:20

Burden, prevalence and prognosis of pancreatic cancer in 2017

S. Barbu

14:20–15:00

Surveillance in patients with hereditary risks or chronic pancreatitis

J. Rosendahl

15:00–15:20

Better diagnosis and treatment?

E. Van Cutsem

15:20–15:40

Patient perspective

A. Stunt

15:40–15:50

Conclusion: What do we need first?

J. Rosendahl

15:50–16:30 Coffee break

16:30–18:00

#### **Other digestive cancers: Next to be screened?**

**Chairs:** L. Dušek, T. Ponchon, P. Burra

16:30–16:55

Screening of Barrett: Is it cost-effective?

Is there a high-risk population?

T. Ponchon

16:55–17:20

Surveillance of hepatocarcinoma in cirrhotic patients

P. Burra

17:20–17:45

Is there a role for screening gastric carcinoma or preneoplastic lesions?

M. Dinis Ribeiro

17:45–18:00

Discussion: Which are the priorities?

T. Ponchon

20:00 Welcome Dinner

**Wednesday, 27 September 2017**

**Symposium in English language**

**CRC screening**

08:30–10:50

**State of the art in Europe**

**Chairs:** P. Poc, M. Van Leerdam, European Commission representative (TBC)

08:30–08:35

Introduction

P. Poc, L. Dušek

08:35–08:50

State of the art in Western Europe

European Commission representative (TBC)

08:50–09:05

State of the art in Eastern Europe

M. Leja

09:05–09:20

Why and how to start a population based CRC screening programme? How to get the government involved and what is its role?

P. Poc

09:20–09:50

Differences between on-going programmes:

- 1) The Netherlands: E. Dekker
- 2) Germany: T. Seufferlein
- 3) Poland: M. Løberg

09:50–10:05

Interactive discussion

10:05–10:50

State of the Art in Czech Republic  
CRC screening: Czech experience in implementation

1) Role of comprehensive cancer care networks in organising colorectal cancer care: Experience from CANCON project  
L. Dušek

2) Lessons learnt from cancer screening programmes as an example for establishing the Czech national coordination centre  
O. Májek

3) Practical challenges in establishing and running the Czech national colorectal cancer screening programme  
T. Grega, O. Májek

10:50 - 11:20 Coffee break

11:20–13:00

**Why and how to start a population based CRC screening programme?**

**Chairs:** S. Spanik, E. Dekker

11:20–11:40

Cost-effectiveness analysis of a screening programme

I. Lansdorp-Vogelaar

11:40–12:00

Lobbying for a screening programme in Eastern Europe

M. J. Marinescu

12:00–12:20

Choice of screening method - factors to take into account

M. van Leerdam

12:20–12:40

Parameters for monitoring  
(Speaker tba)

12:40–13:00

Quality assurance and logistic organisation of a programme

F. de Bels

13:00–14:00 Lunch break

14:00–15:50

**Optimizing participation in ongoing CRC-screening programmes**

**Chairs:** B. Seifert, L. Dušek

14:00–14:20

State of the art of the participation in Europe  
N. Segnan

14:20–15:50

Why do we have different levels of participation in Europe?

1) Influence of the programme design

Pro GP implication: F. de Bels

Cons GP implication: E. Dekker

2) Influence of the population type

How to tackle inequalities

S. Halloran

3) Influence of the message

J. Wilkes

4) Influence of the patient associations and/or  
influence of a champion

L. Colemont

**15:50–16:00**

**Conclusions**

**Chairs:** L. Dušek, T. Ponchon

**Faculty for Tuesday/Wednesday**

Sorin Barbu (Romania)  
Patrizia Burra (Italy)  
Frederic de Bels (France)  
Evelien Dekker (The Netherlands)  
Mario Dinis Ribeiro (Portugal)  
Ladislav Dušek (Czech Republic)  
Stephen Patrick Halloran (United Kingdom)  
Iris Lansdorp-Vogelaar (The Netherlands)  
Marcis Leja (Latvia)  
Magnus Løberg (Norway)  
Ondřej Májek (Czech Republic)  
Nuria Malats (Spain)  
Thierry Ponchon (France)  
Jonas Rosendahl (Germany)  
Nereo Segnan (Italy)  
Bohumil Seifert (Czech Republic)  
Thomas Seufferlein (Germany)  
Stanislav Špánik (Slovakia)  
Tomáš Grega (Czech Republic)  
Eric Van Cutsem (Belgium)  
Monique van Leerdam (The Netherlands)  
Miroslav Zavoral (Czech Republic)  
Luc Colemont (Stop Darmkanker)  
Pavel Poc (MEP)  
Marian-Jean Marinescu (MEP)  
Ali Stunt (Pancreatic Cancer Europe)  
Justin Wilkes (Spink Health)